We have developed bioactive bone cements manufactured from bioactive glass-ceramic powder and BIS-GMA resin, which has the bone-bonding ability. In the present clinical trial, this bioactive bone cement was used for fixation of total hip arthroplasty (THA) and the clinical results were investigated

Two types of bioactive bone cements (high- and low- viscosity type cements) were prepared (Nippon Electric Glass Co. Ltd.). Inorganic filler contained 72.0 wt% AW-GC (apatite and wollastonite containing glass-ceramic) and 27.0 wt% SiO2 powder. All surgery was performed at Kyoto University Hospital between February and October 1996. 20primary THA (20 patients) were performed using bioactive bone cement as a clinical trial. The average age of the patients was 58 years. The average follow-up period was 6 years, 9 months. The diagnosis for 18 hips at the operation was osteoarthritis and 2 hips were rheumatoid arthritis. All sockets and one stem were fixed by bioactive cement, and all but one stem were fixed by PMMA cement. In all cases all polyethylene socket and titanium stem were used (14 KC type THA and 8 KMAX type THA). For the femoral head 22 mm diameter alumina head was used in all cases.

If the bone cement is bioactive and shows direct bonding with the bone, wear particles can’t enter the interface and thus prevention of loosening due to bone resorption would be expected. This cement demonstrated satisfactory clinical results, proving to be a promising material for implant fixation.